Displaying results 37 - 48 of 87
Public Health and Advocacy
EASL Policy Statement on Hepatitis C Elimination - PL

EASL Policy Statement on Hepatitis C Elimination - PL

PDF
View
Public Health and Advocacy
EASL Policy Statement on Hepatitis C Elimination - PT

EASL Policy Statement on Hepatitis C Elimination - PT

PDF
View
Public Health and Advocacy
EASL Policy Statement on Hepatitis C Elimination - RO

EASL Policy Statement on Hepatitis C Elimination - RO

PDF
View
Public Health and Advocacy
EASL Policy Statement on Hepatitis C Elimination - RU

EASL Policy Statement on Hepatitis C Elimination - RU

PDF
View
Public Health and Advocacy
EASL Policy Statement: risk-based surveillance for hepatocellular carcinoma among patients with cirrhosis

EASL Policy Statement: risk-based surveillance for hepatocellular carcinoma among patients with cirrhosis

PDF
View
Public Health and Advocacy
EASL Policy Statement: Reducing alcohol harms

EASL Policy Statement: Reducing alcohol harms

PDF
View
Public Health and Advocacy
EASL Policy Dialogues S2 E2: World Liver Day

EASL Policy Dialogues S2 E2: World Liver Day

EASL Policy Dialogues
View
Public Health and Advocacy
EASL Policy Dialogues Episode 1: Drug use, viral hepatitis, and Europe

EASL Policy Dialogues Episode 1: Drug use, viral hepatitis, and Europe

EASL Policy Dialogues
View
Public Health and Advocacy
EASL Policy Dialogues Episode 3: Liver cancer: The risk of ignorance

EASL Policy Dialogues Episode 3: Liver cancer: The risk of ignorance

EASL Policy Dialogues
View
Liver Tumours
EASL Studio S1 E1: Liver Cancer Awareness Month

EASL Studio S1 E1: Liver Cancer Awareness Month

EASL Studio
View
Metabolism, Alcohol & Toxicity

Introduction and presentation of the NAFLD patient guideline

Webcasts
View
Metabolism, Alcohol & Toxicity

The user perspective

Webcasts
View